| Literature DB >> 24898549 |
Carola H Ries1, Michael A Cannarile2, Sabine Hoves2, Jörg Benz3, Katharina Wartha2, Valeria Runza2, Flora Rey-Giraud2, Leon P Pradel2, Friedrich Feuerhake4, Irina Klaman2, Tobin Jones2, Ute Jucknischke2, Stefan Scheiblich2, Klaus Kaluza2, Ingo H Gorr2, Antje Walz5, Keelara Abiraj5, Philippe A Cassier6, Antonio Sica7, Carlos Gomez-Roca8, Karin E de Visser9, Antoine Italiano10, Christophe Le Tourneau11, Jean-Pierre Delord8, Hyam Levitsky12, Jean-Yves Blay6, Dominik Rüttinger2.
Abstract
Macrophage infiltration has been identified as an independent poor prognostic factor in several cancer types. The major survival factor for these macrophages is macrophage colony-stimulating factor 1 (CSF-1). We generated a monoclonal antibody (RG7155) that inhibits CSF-1 receptor (CSF-1R) activation. In vitro RG7155 treatment results in cell death of CSF-1-differentiated macrophages. In animal models, CSF-1R inhibition strongly reduces F4/80(+) tumor-associated macrophages accompanied by an increase of the CD8(+)/CD4(+) T cell ratio. Administration of RG7155 to patients led to striking reductions of CSF-1R(+)CD163(+) macrophages in tumor tissues, which translated into clinical objective responses in diffuse-type giant cell tumor (Dt-GCT) patients.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24898549 DOI： 10.1016/j.ccr.2014.05.016
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743